SCHEMBL2947288

SCHEMBL2947288

CCCSc1ccc2nc(-c3ccc(OCCOC)cc3)cn2n1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 6/20 0.48
TP53 P04637 5/20 0.48
MAPT P10636 4/20 0.48
LMNA P02545 5/20 0.47
NPC1 O15118 5/20 0.46
RAB9A P51151 5/20 0.46
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
PKM P14618 2/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
POLB P06746 1/20 0.43
HRH3 Q9Y5N1 3/20 0.42
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2953031 0.81 NPC1 (0.51) RXFP1TP53MAPTNPC1RAB9A
SCHEMBL2952526 0.79 NPC1 (0.43) RXFP1TP53MAPTLMNANPC1
SCHEMBL2946483 0.79 HRH3 (0.47) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL13236507 0.76 HRH3 (0.52) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL13236495 0.74 NPC1 (0.48) TP53MAPTNPC1RAB9AKDM4E
SCHEMBL2945335 0.73 PDE10A (0.42) RXFP1NPC1RAB9AKDM4EALDH1A1
SCHEMBL2954578 0.68 NPC1 (0.60) RXFP1TP53MAPTLMNANPC1
SCHEMBL20370812 0.67 NPC1 (0.75) MAPTLMNANPC1RAB9AKDM4E
SCHEMBL12855179 0.65 HRH3 (0.68) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL44776 0.65 CSNK1D (0.36) NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759349-B2 Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) 2010-07-20 US disclosed
US-7759349-B2 Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) 2010-07-20 US disclosed
US-7759349-B2 Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) 2010-07-20 US disclosed
EP-1699799-B1 CONTROL OF PARASITES IN ANIMALS BY THE USE OF IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES SCHERING PLOUGH LTD (CH) 2007-05-16 EP disclosed
EP-1699799-A1 CONTROL OF PARASITES IN ANIMALS BY THE USE OF IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES Schering-Plough Ltd. (CH) 2006-09-13 EP disclosed
US-20050182059-A1 Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives SCHERING-PLOUGH ANIMAL HEALTH CORPORATION 2005-08-18 US disclosed
WO-2005066177-A1 CONTROL OF PARASITES IN ANIMALS BY THE USE OF IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES SCHERING-PLOUGH LTD. (CH) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182059-A1 Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives PLPBP, PIR, PPIP5K2 RXFP1 2721/4885TP53 4364/4885MAPT 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.